SRR5088888
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.500
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- MITOTIC_SPINDLE+0.300
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.200
- ANGIOGENESIS+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- APICAL_SURFACE-0.400
- ESTROGEN_RESPONSE_LATE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- ADIPOGENESIS-0.200
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- COAGULATION-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- FATTY_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.795 |
| 2 | SRR8613747 | — | D | 0.792 |
| 3 | MNG289 | — | — | 0.759 |
| 4 | a7e776a3-4159-4cf7-8e05-2c2202330f58 | — | — | 0.757 |
| 5 | SRR934900 | — | — | 0.753 |
| 6 | SRR934744 | — | — | 0.750 |
| 7 | 3e94d9d5-8c59-4366-babb-193bdc57d661 | — | — | 0.743 |
| 8 | SRR12202460 | — | — | 0.741 |
| 9 | TCGA-AN-A0G0-01A-11R-A034-07 | — | E | 0.734 |
| 10 | TCGA-A8-A07B-01A-11R-A00Z-07 | — | C | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |